Fosaprepitant

Fosaprepitant

Systematic (IUPAC) name
[3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo- 2H-1,2,4-triazol-1-yl]phosphonic acid
Clinical data
AHFS/Drugs.com	Multum Consumer Information
MedlinePlus	a604003
Licence data	EMA:Link, US FDA:link
Pregnancy category	US: B (No risk in non-human studies)
Legal status	UK: POM (Prescription only) US: ℞-only
Routes of administration	Intravenous
Pharmacokinetic data
Bioavailability	n/a
Protein binding	>95% (aprepitant)
Metabolism	To aprepitant
Biological half-life	9 to 13 hours (aprepitant)
Identifiers
CAS Number	172673-20-0 Y Template:CAS (dimeglumine)
ATC code	A04AD12 (WHO)
PubChem	CID: 219090
IUPHAR/BPS	7623
DrugBank	DB06717 N
UNII	6L8OF9XRDC N
KEGG	D06597 N
ChEMBL	CHEMBL1199324 N
Chemical data
Formula	C23H22F7N4O6P
Molecular mass	614.406 g/mol
NY (what is this?)  (verify)

Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant.

Fosaprepitant was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25, 2008 and by the European Medicines Agency (EMA) on January 11 of the same year.

See also

• Aprepitant
• Casopitant
• L-733,060
• Maropitant
• Vestipitant

References

1. REDIRECT Template:Peptide receptor modulators